Joinn Biologics nabs $60M to use for biologics capacity

A Chinese-American CDMO has raised $60 million but doesn’t intend to hold onto the cash very long. Joinn Biologics says it will use most of it to build a plant to increase its biologics production, including its cell lines for new generation drugs.